GMAB Genmab - ADR

24.12
-0.02  -0%
Previous Close 24.14
Open 24.14
Price To Book 8.49
Market Cap 15,656,432,137
Shares 649,105,810
Volume 217,405
Short Ratio
Av. Daily Volume 232,119
Stock charts supplied by TradingView

NewsSee all news

  1. Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

    Company Announcement Genmab to receive milestone payment of USD 100 Million in DARZALEX collaboration Milestone triggered by sales of DARZALEX reaching USD 2.5 billion in a calendar year Copenhagen, Denmark; December

  2. Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

    Company Announcement DARZALEX® approved in Europe in combination with lenalidomide and dexamethasone as treatment for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell

  3. David Eatwell to Retire as Chief Financial Officer of Genmab

    Company Announcement David Eatwell has decided to retire on February 29, 2020Anthony Pagano, Senior Vice President Finance and Corporate Development will be promoted to Executive Vice President and CFO, effective

  4. CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

    Company Announcement CHMP issued a positive opinion for DARZALEX® in combination with lenalidomide and dexamethasone as treatment for newly diagnosed adult patients with multiple myeloma who are ineligible for

  5. Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019

    Company Announcement Net sales of DARZALEX in the third quarter of 2019 totaled USD 765 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 15, 2019 –

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 1H 2020.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
Phase 3 data met endpoints - August 30, 2019. Data presented at ECTRIMS September 13, 2019 noted reduction in annualized relapse rate (ARR) by 50.5% and 58.8% compared to Aubagio.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer
FDA Approval announced June 28, 2019.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
sBLA filing announced July 12, 2019. PDUFA estimate May 12, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Phase 3 data met primary endpoint - September 13, 2019. LBA at ASH December 10, 2019, 7:30 AM.
KYPROLIS (CANDOR)
Multiple Myeloma
FDA Approval announced September 26, 2019.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Phase 1/2 initial data presented at IASLC 2019 WCLC September 8, 2019.
Enapotamab vedotin
Solid tumors
Phase 1/2 initial data to be presented at ASH December 8, 2019.
HexaBody-DR5/DR5
Solid tumors
Phase 1/2 initial data to be presented at ASH December 9, 2019.
GEN3013 (DuoBody-CD3xCD20)
B-cell Lymphoma

Latest News

  1. Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

    Company Announcement Genmab to receive milestone payment of USD 100 Million in DARZALEX collaboration Milestone triggered by sales of DARZALEX reaching USD 2.5 billion in a calendar year Copenhagen, Denmark; December

  2. Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

    Company Announcement DARZALEX® approved in Europe in combination with lenalidomide and dexamethasone as treatment for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell

  3. David Eatwell to Retire as Chief Financial Officer of Genmab

    Company Announcement David Eatwell has decided to retire on February 29, 2020Anthony Pagano, Senior Vice President Finance and Corporate Development will be promoted to Executive Vice President and CFO, effective

  4. CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

    Company Announcement CHMP issued a positive opinion for DARZALEX® in combination with lenalidomide and dexamethasone as treatment for newly diagnosed adult patients with multiple myeloma who are ineligible for

  5. Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019

    Company Announcement Net sales of DARZALEX in the third quarter of 2019 totaled USD 765 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 15, 2019 –

  6. Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma

    Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with bortezomib, thalidomide (an immunomodulatory agent) and dexamethasone as treatment for patients newly diagnosed with multiple myeloma

  7. Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma

    Company Announcement Phase III CANDOR study of daratumumab in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma met the primary endpoint of improvement in progression free

  8. Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS

    Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) versus teriflunomide in patients with relapsing multiple sclerosis (RMS) were presented at the 35th Congress of the

  9. Genmab and Tempus Enter into Strategic Collaboration Agreement

    Media Release Copenhagen, Denmark, September 9, 2019 Genmab and Tempus sign agreement to research and develop novel targets Genmab A/S (NASDAQ:GMAB) announced today that it has entered into a strategic collaboration